Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Inhibikase Therapeutics, Inc. (IKT) is reported to have 14,653,994 shares of common stock beneficially owned for Section 13(d) purposes by reporting persons including RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, who expressly disclaim status as a group.
The Fund directly holds 6,970,000 shares of common stock and Pre-Funded Warrants exercisable for up to 18,030,000 shares, subject to a Beneficial Ownership Blocker that limits ownership to 9.99% of outstanding common stock. The Fund is currently prohibited from exercising the Pre-Funded Warrants to the extent such exercise would result in beneficial ownership of more than 7,683,994 shares of common stock.
The ownership percentage is based on 132,032,636 shares outstanding as of May 1, 2026, plus 25,000,000 shares issued to the Fund on July 10, 2026, less 18,030,000 shares surrendered in exchange for Pre-Funded Warrants on July 29, 2026, and giving effect to warrants exercisable within 60 days. Due to EDGAR field limits, Row 11 shows 9.9%. Voting and dispositive power over the securities is shared among the reporting persons, and several of them disclaim beneficial ownership beyond determining their Section 13(d) obligations.
Inhibikase Therapeutics, Inc. ten percent owner RA Capital Healthcare Fund, L.P. entered an Exchange Agreement on July 29, 2026, swapping 18,030,000 shares of Common Stock for a Pre-Funded Warrant exercisable for up to 18,030,000 shares at $0.001 per share. After this disposition, the Fund holds 6,970,000 shares of Common Stock. The Pre-Funded Warrant is immediately exercisable, has no expiration date, and includes a 9.99% beneficial ownership limitation for the Fund and its Attribution Parties. RA Capital Management, L.P., its general partner and principals Peter Kolchinsky and Rajeev Shah are also reporting persons and each disclaims beneficial ownership beyond respective pecuniary interests.
Inhibikase Therapeutics director Dennis N. Berman exercised stock options covering 21,854 shares of common stock on July 30, 2026 at an exercise price of $1.26 per share. The fully vested options were converted, leaving 0 options from this grant and 21,854 common shares held directly.
Inhibikase Therapeutics, Inc. entered into an exchange agreement with RA Capital Healthcare Fund, L.P. on July 29, 2026. RA Capital exchanged 18,030,000 shares of common stock for a pre-funded warrant to acquire 18,030,000 shares of common stock.
The pre-funded warrant has a $0.001 exercise price per share, is immediately exercisable, has no expiration date, and is adjustable for stock splits and similar events. A beneficial ownership blocker generally limits RA Capital’s ownership upon exercise to 9.99% of outstanding common stock, adjustable with 61 days’ notice up to 19.99%. The warrant was issued in an unregistered exchange relying on Section 3(a)(9) of the Securities Act of 1933.
BlackRock, Inc. reported beneficial ownership of 7,768,004 shares of Inhibikase Therapeutics, Inc. common stock, representing 5.9% of the outstanding class as of June 30, 2026.
BlackRock has sole voting power over 7,680,732 shares and sole dispositive power over 7,768,004 shares, with no shared voting or dispositive power. The holdings are attributed to certain BlackRock business units, and various underlying persons have rights to dividends or sale proceeds, but no single one exceeds 5% of the outstanding shares.
Inhibikase Therapeutics, Inc. reports that the FDA’s Office of Orphan Products Development has granted Orphan Drug Designation to its lead candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension (PAH), a rare, progressive cardiopulmonary disease affecting approximately 50,000 people in the United States.
The company cites preclinical data showing improvements in pulmonary vascular and hemodynamic markers of PAH and a lower potential for GI toxicity compared with imatinib mesylate. Orphan status can provide incentives including tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of U.S. market exclusivity upon regulatory approval. IKT-001 is being evaluated in IMPROVE-PAH, a single pivotal Phase 3 study at approximately 180 sites worldwide that is actively enrolling patients.
Inhibikase Therapeutics, Inc. has a major shareholder group associated with RA Capital reporting indirect ownership of 25,000,000 shares of common stock as of July 10, 2026.
The shares are held directly by RA Capital Healthcare Fund LP, with RA Capital Management as investment manager and its principals Dr. Peter Kolchinsky and Mr. Rajeev Shah as managing members, each disclaiming beneficial ownership beyond their pecuniary interest.
Inhibikase Therapeutics, Inc. is reported to have 25,000,000 shares of its common stock held by RA Capital Healthcare Fund, L.P., with RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah as associated reporting persons. This position represents 15.9% of Inhibikase’s common stock.
The percentage is based on 132,032,636 shares outstanding as of May 1, 2026, plus 25,000,000 additional shares issued to the Fund in an at-the-market offering on July 10, 2026. The Fund has delegated sole voting and dispositive power over these shares to RA Capital and disclaims beneficial ownership, while the other reporting persons also disclaim beneficial ownership except for Section 13(d) reporting purposes.
Inhibikase Therapeutics, Inc. disclosed that it sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market facility, generating gross proceeds of $50 million under an existing shelf registration statement on Form S-3 and related ATM prospectus supplement.
The company expects this additional capital, together with existing cash reserves, to support operations through topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH trial of IKT-001 for Pulmonary Arterial Hypertension, subject to the full exercise of outstanding Series A and B Warrants.
Inhibikase is a clinical-stage pharmaceutical company developing IKT-001, a prodrug of imatinib, for Pulmonary Arterial Hypertension, a progressive, life-threatening disease that affects approximately 50,000 Americans, with its single pivotal Phase 3 IMPROVE-PAH study actively enrolling at about 180 sites worldwide.
Inhibikase Therapeutics director Dennis N. Berman received a stock option grant covering 155,000 shares of common stock. The option has an exercise price of $1.91 per share and expires on June 26, 2036.
The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service as a director through that date. After this grant, Berman holds stock options for 155,000 underlying shares directly.